Uniqure NV (NASDAQ:QURE) insider Deventer Sander Van sold 5,985 shares of the firm’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $18.53, for a total transaction of $110,902.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Uniqure NV (QURE) traded down $0.44 on Wednesday, reaching $19.07. 56,482 shares of the company’s stock traded hands, compared to its average volume of 404,955. Uniqure NV has a 12-month low of $4.72 and a 12-month high of $21.35. The company has a current ratio of 3.64, a quick ratio of 3.64 and a debt-to-equity ratio of 0.73. The company has a market capitalization of $578.12, a P/E ratio of -7.41 and a beta of 0.72.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.25. Uniqure had a negative net margin of 338.39% and a negative return on equity of 170.28%. analysts forecast that Uniqure NV will post -2.97 earnings per share for the current fiscal year.
A number of analysts have weighed in on the stock. Janney Montgomery Scott assumed coverage on shares of Uniqure in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $25.00 target price on the stock. ValuEngine upgraded shares of Uniqure from a “sell” rating to a “hold” rating in a report on Monday, January 1st. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Zacks Investment Research raised shares of Uniqure from a “sell” rating to a “hold” rating and set a $21.00 price target for the company in a research note on Tuesday, October 24th. Finally, HC Wainwright set a $28.00 price target on shares of Uniqure and gave the company a “buy” rating in a research note on Thursday, December 7th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $20.00.
Institutional investors and hedge funds have recently bought and sold shares of the business. OxFORD Asset Management LLP bought a new stake in Uniqure in the third quarter valued at $399,000. JPMorgan Chase & Co. increased its stake in Uniqure by 33.5% in the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 14,659 shares in the last quarter. FMR LLC increased its stake in Uniqure by 4.1% in the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares in the last quarter. Mangrove Partners increased its position in shares of Uniqure by 167.4% during the third quarter. Mangrove Partners now owns 106,634 shares of the biotechnology company’s stock worth $1,024,000 after acquiring an additional 66,763 shares in the last quarter. Finally, First Manhattan Co. bought a new stake in shares of Uniqure during the fourth quarter worth about $1,371,000. 24.95% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Uniqure NV (QURE) Insider Sells $110,902.05 in Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/31/uniqure-nv-qure-insider-sells-110902-05-in-stock.html.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.